Navigation Links
Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
Date:12/16/2008

percent of patients and were severe (NCI-CTC grade 3 and higher) in 12 percent of patients receiving Vectibix monotherapy. Withhold Vectibix for dermatologic toxicities that are grade 3 or higher or are considered intolerable. If toxicity does not improve to ¿ grade 2 within 1 month, permanently discontinue Vectibix. The clinical manifestations included, but were not limited to, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage were reported.

Infusion Reactions: Severe infusion reactions occurred in approximately 1 percent of patients. Severe infusion reactions included anaphylactic reactions, bronchospasm, and hypotension. Although not reported with Vectibix, fatal infusion reactions have occurred with other monoclonal antibody products. Stop infusion if a severe infusion reaction occurs. Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Look
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The November 2014 issue of BioTechniques ( ... journal featuring the following articles:, , ... in the retina , DNA from fingermarks ... chromogenic substrates in zebrafish , Re-use of ... , Nuclear LC3-positive puncta in stressed cells ...
(Date:11/21/2014)... 2014 Why did Stephen Hawking become ... so instantly recognizable? Why have they become icons to ... author Hilton Ratcliffe seeks out the answers to those ... to do with science. In " Stephen Hawking Smoked ... 21, 2014), Ratcliffe puts it plainly: , “It ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... is a professional and in-depth research report on ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:11/21/2014)... 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the ... it has closed a brokered private placement offering ... C$3.7 million.  Cormark Securities Inc. and Clarus Securities ... Offering for a syndicate of agents that also ... (collectively the "Agents"). Concurrently with the Brokered Offering, ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... International,Corporation (Nasdaq: PRXL ) will release Second Quarter ... after the close of the,stock market. The announcement will ... on the PR Newswire website at, http://www.prnewswire.com ., ... at 10:00 a.m. ET,on Thursday, January 24, 2008 to ...
... update on QuatRx clinical development programs, including review of positive ... ... ANN ARBOR, Mich., Jan. 4 QuatRx Pharmaceuticals Company,today announced ... a presenter at the 26th Annual JP Morgan Healthcare,Conference on Tuesday, ...
... BOSTON, Jan. 4 Follica Inc., a privately ... (male and female pattern hair,loss caused by androgens ... follicle disorders, today announced a $5.5 million Series ... existing,investors PureTech Ventures participated. The funding is expected ...
Cached Biology Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call 2QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference 2Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic 2Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic 3
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/3/2014)... Researchers from Australia report that low birth weight and ... (OA)-related hip replacements in adulthood. Findings published in the ... & Research , indicate that low birth weight and ... arthroplasty due to OA as adults. , According ... of 25 are diagnosed with clinical OA. Symptoms of ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... 23, 2010) A clue to the causes of ... tiny intercellular junction that rapidly transfers information from one ... University School of Medicine, with students from the Sackler ... called APC (adenomatous polyposis coli) plays a key role ...
... viral genes protected monkeys infected with deadly Ebola or ... therapeutics were administered one hour after exposuresuggesting the approach ... hospital settings. The research, which appears in today,s ... was conducted by the U.S. Army Medical Research Institute ...
... the University of Minnesota Academic Health Center have identified two ... for HIV. The two drugs, decitabine and gemcitabine ... therapy were found to eliminate HIV infection in the ... death an outcome researchers dubbed "lethal mutagenesis." This ...
Cached Biology News:Researchers connect APC protein to autism and mental retardation 2Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 2Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 3U of M researchers identify 2 FDA approved drugs that may fight HIV 2
... that will help protect your PCR runs ... work area prior to use, reducing the ... Containment features reduce the chance of airborne ... for a clear view, an acid-resistant black ...
...
... glass slide in this set of ... in triplicate, for a total of ... proteins as internal control. Antibodies belonging ... angiogenesis, apoptosis, cell cycle progression, signal ...
...
Biology Products: